Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
CDMO
491 Articles Available
1
21
Can't find what you're looking for? Try our
advanced search
.
Microbiome CDMO
Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products
PAP-Q3-20-CL-004
Parenterals
Trends Shaping the Dynamic Market for Parenterals
PAP-Q3-20-CL-018
Integrated CDMO
Building an Integrated and Effective CDMO from the Ground Up
PAP-Q3-20-CL-027
Recombinant Proteins
Innovation and Flexibility Drive Success During the COVID-19 Pandemic
PAP-Q3-20-CL-019
Collaboration
Better Together: Collaborating to Simplify Complexities in Drug Development
PAP-Q3-20-CL-028
Feature Story
The Growing Importance of Local Manufacturing and Nearby Outsourcing Partners
PAP-Q3-20-NI-003
The Future of Healthcare
How Is FEC Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-008
The Future of Healthcare
How Is Pii Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-005
The Future of Healthcare
How Is Arranta Bio Evolving its Business Model to Meet the Future of Healthcare?
PAP-Q3-20-RT2-009
COVID-19
Rethinking Pharma’s Responsibilities in a Time of Crisis
PAP-Q2-20-CL-001
CDMO
Positioning a CDMO to Meet Future Needs
PAP-Q2-20-CL-006
Aseptic Manufacturing
Aseptic Manufacturing with State-of-the-Art Technologies
PAP-Q2-20-CL-011
Investment
Investing at the Intersection of Industrial Manufacturing and Healthcare
PAP-Q2-20-CL-025
HPAPIs
Essentials of an Industry-Leading CDMO Partner for Highly Potent Projects
PAP-Q2-20-CL-031
COVID-19
What’s Next for the Supply Chain Post-Pandemic
PAP-Q2-20-CL-033
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
PR-M06-20-NI-008
Western Partner
Simplifying the Supply Chain with Large-Volume Western CDMO Partners
PA0-CL-0420-001
COVID-19
COVID-19: A Look at the Virus, its Epidemiology, Therapeutic and Vaccine Development Efforts and Impacts of the Pandemic
PAO-Q2-20-NI-001
Pharmaceutics Know-How
Pharmaceutics Know-How and Service Excellence to Re-Energize a CDMO
PAP-Q1-20-CL-001
CDMO Leadership
A Vision for Achieving Worldwide Biopharmaceutical CDMO Leadership
PAP-Q1-20-CL-003
Virtual Panel
Leveraging a Biomanufacturing Legacy to Support New Business
PAP-Q1-20-CL-005
Business Models
CDMO Services Designed to Support Evolving Pharma Business Models
PAP-Q1-20-CL-007
Outsourcing
Current Trends & Future Prospects in Outsourced Pharmaceutical Manufacturing
PAP-Q1-20-CL-027
CDMO
The Future of the CDMO Market: The Art of the Possible
PAP-Q1-20-CL-035
1
21
»
